<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445103</url>
  </required_header>
  <id_info>
    <org_study_id>68999970512</org_study_id>
    <nct_id>NCT04445103</nct_id>
  </id_info>
  <brief_title>The Malaria Heart Disease Study</brief_title>
  <official_title>The Malaria Heart Disease Study: A Novel Pathway to Subclinical Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Acre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Malaria Heart Disease Study is a prospective longitudinal cohort study of a random sample&#xD;
      of approximately 1200 individuals from the state of Acre in Brazil. The overall hypothesis is&#xD;
      that patients who have (i) previously suffered from a malaria infection or (ii) patients with&#xD;
      ongoing symptomatic malaria will benefit from having an echocardiogram and blood tests&#xD;
      performed as a screening tool to diagnose early cardiac impairment and prevent future&#xD;
      cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the relationship between exposure to malaria and&#xD;
      the risk of developing subclinical and manifest cardiovascular disease. The study is&#xD;
      conducted in the high endemic malaria zone pertaining to the city of Cruzeiro do Sul, located&#xD;
      in the state of Acre, Brazil. The city is considered a part of the Amazon basin.&#xD;
&#xD;
      By invitation of a random sample of patients with a history of malaria, controls with no&#xD;
      history of malaria, and symptomatic patients with ongoing malaria infection, the aim is to&#xD;
      elucidate potential pathways linking malaria to cardiovascular disease.&#xD;
&#xD;
      Aim 1: Determine whether prior exposure to malaria is associated with myocardial dysfunction.&#xD;
      The investigators hypothesize that adults with a history of treated malaria (cases) will have&#xD;
      worse left ventricular (LV) diastolic function and systolic strain compared to age- and&#xD;
      sex-matched controls without a history of malaria infection. The investigators will recruit&#xD;
      500 cases and 500 controls from Cruzeiro-do-Sul, Brazil. State-of-the-art ultrasonographic&#xD;
      examinations will be used to asses novel imaging metrics of cardiac function.&#xD;
&#xD;
      Aim 2: Define the extent to which proinflammatory factors (such as Ang-2, CRP, VEGF) are&#xD;
      associated with cardiac dysfunction in subjects with a history of malaria. The investigators&#xD;
      hypothesize that proinflammatory biomarkers will be higher in cases compared to controls, and&#xD;
      that higher concentrations of inflammatory markers will associate with worse LV diastolic&#xD;
      function and strain. The investigators will measure inflammatory biomarkers, determine the&#xD;
      association with cardiac dysfunction, and test whether history of malaria modifies this&#xD;
      association.&#xD;
&#xD;
      Aim 3: Determine if echocardiographic parameters of systolic and diastolic function and&#xD;
      cardiac biomarkers are significantly elevated in patients with symptomatic malaria (N=200).&#xD;
&#xD;
      Upon conclusion of this study, the investigators will better understand the relationship of&#xD;
      malaria with subclinical cardiac dysfunction. This will allow development of the scientific&#xD;
      foundation and necessary infrastructure to expand this project to a longitudinal study to&#xD;
      prospectively assess associations with relevant clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2020</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>2020-2023</time_frame>
    <description>Alterations in systolic and diastolic function assessed by conventional and speckle tracking echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>2020-2023</time_frame>
    <description>Elevated cardiac biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial dysfunction</measure>
    <time_frame>2020-2023</time_frame>
    <description>Elevated markers of endothelial dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>2020-2023</time_frame>
    <description>Elevated proinflammatory markers</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Plasmodium Falciparum</condition>
  <condition>Plasmodium Vivax</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>History of malaria</arm_group_label>
    <description>Individuals with a history of malaria infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Individuals without a history of malaria infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic malaria</arm_group_label>
    <description>Patients with symptomatic malaria infection (complicated and uncomplicated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment of cardiac function</intervention_name>
    <description>Echocardiographic examination and assessment of cardiac biomakers</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>History of malaria</arm_group_label>
    <arm_group_label>Symptomatic malaria</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population conforms to three study groups: i) History of malaria infection ii)&#xD;
        Controls and iii) Symptomatic malaria infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1 (History of malaria) Inclusion: Patients with a record of malaria &gt;=18 years old&#xD;
        will be invited at random Exclusion: Persons not able to cooperate and persons unwilling or&#xD;
        unable to understand and sign &quot;informed consent&quot;, persons who are hospitalized due to&#xD;
        severe malaria&#xD;
&#xD;
        Group 2 (Controls) Inclusion: Patients with no record of malaria &gt;=18 years old will be&#xD;
        invited at random Exclusion: Persons not able to cooperate and persons unwilling or unable&#xD;
        to understand and sign &quot;informed consent&quot;&#xD;
&#xD;
        Group 3 (Symptomatic malaria) Inclusion: Patients &gt;=18 years old diagnosed in&#xD;
        outpatient/inpatient clinic with malaria infection by thick and thin blood smear and/or&#xD;
        rapid diagnostic test. Enrollment of both severe (complicated) and uncomplicated malaria&#xD;
        cases as defined by the WHO criteria. Exclusion: Persons not able to cooperate and persons&#xD;
        unwilling or unable to understand and sign &quot;informed consent&quot;, suspected or verified&#xD;
        concomitant protozoal infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Brainin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Acre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odilson Silvestre, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Acre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tor Biering-SÃ¸rensen, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Brainin, MD, PhD</last_name>
    <phone>+45 29425299</phone>
    <email>denlillefilur@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Philip Brainin</name>
      <address>
        <city>Cruzeiro do Sul</city>
        <state>Acre</state>
        <zip>69980000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Brainin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2020</study_first_submitted>
  <study_first_submitted_qc>June 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Philip Brainin</investigator_full_name>
    <investigator_title>Philip Brainin, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Echocardiography</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Cardiovascular inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

